Chronic venous disease and diabetic microangiopathy: pathophysiology and commonalities.
Journal
International angiology : a journal of the International Union of Angiology
ISSN: 1827-1839
Titre abrégé: Int Angiol
Pays: Italy
ID NLM: 8402693
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
pubmed:
23
9
2021
medline:
15
12
2021
entrez:
22
9
2021
Statut:
ppublish
Résumé
Chronic venous disease and diabetes mellitus are highly prevalent and debilitating conditions affecting millions of individuals globally. Although these conditions are typically considered as separate entities, they often co-exist which may be important in both understanding their pathophysiology and determining the best treatment strategy. Diabetes mellitus is twice as common in patients with chronic venous disease compared with the general population. Notably, a large proportion of patients with diabetes mellitus present with venous disorders, although this is often overlooked. The etiology of chronic venous disease is multifactorial, involving hemodynamic, genetic, and environmental factors which result in changes to the venous endothelium and structural wall as well as inflammation. Inflammation, endothelial dysfunction and hyperfiltration or leakage, are commonly observed in diabetes mellitus and cause various diabetic microvascular complications. Both diseases are also influenced by the increased expression of adhesion molecules, chemokines, and cytokines, and are characterized by the presence of vessel hypertension. Consequently, despite differences in etiology, the pathophysiology of both chronic venous disease and diabetic microangiopathy appears to be driven by endothelial dysfunction and inflammation. Treatment strategies should take the co-existence of chronic venous disease and diabetic microangiopathy into account. Compression therapy is recommended in inflammatory conditions that have an edema component as seen in both chronic venous disease and diabetes mellitus. Lifestyle changes like weight loss and exercise, will improve metabolic state and lower inflammation and should be promoted in these patients. Additionally, both patient populations may benefit from venoactive drugs.
Identifiants
pubmed: 34547884
pii: S0392-9590.21.04664-2
doi: 10.23736/S0392-9590.21.04664-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM